Care
Mother and child

Where patients, partners, and quality matter

For over 75 years, Lannett has been proudly providing high-quality, affordable generic pharmaceutical products to patients who depend on them.

Learn More

h

Patient Support

We manufacture over 100 unique pharmaceutical product families for a wide range of therapeutic areas, with many more in development. Our philosophy? Patients first.

Learn More

h

Our Approach

Many of our patients will never know they are taking one of our medicines. But we know. That’s why we strive for the highest quality standards in our pharmaceutical products.

Learn More

h

Careers

Our culture combines a legacy of quality with an appetite for innovation. We’re looking for motivated, engaged individuals to help make the medicines that save and enhance lives.

Learn More

h

Spotlight

April 1, 2021

Lannett Submits ANDA For Generic ADVAIR DISKUS®

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. Food and Drug Administration (FDA), by its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The product is the generic equivalent of ADVAIR DISKUS® of GlaxoSmithKline. Total U.S. sales of the product, according to IQVIA market, were approximately $3 billion for the 12 months ending February 2021, although actual generic market values are expected to be lower.

ADVAIR DISKUS® and Flovent® Diskus® are registered trademarks of GlaxoSmithKline.

Learn More